Matthew Wakefield

Preclinical small molecule WEHI-7326 overcomes drug resistance and elicits response in patient-derived xenograft models of human treatment-refractory tumors.

Christoph Grohmann, Francesca Walker, Mark Devlin, Meng-Xiao Luo, Anderly C Chüeh, Judy Doherty, François Vaillant, Gwo-Yaw Ho, Matthew J Wakefield, Clare E Weeden, Alvin Kamili, Jayne Murray, Sela T Po'uha, Janet Weinstock, Serena R Kane, Maree C Faux, Esmee Broekhuizen, Ye Zheng, Kristy Shield-Artin, Nadia J Kershaw, et al.

Journal article  |  2021  |  Cell Death & Disease

Targeting cell division by chemotherapy is a highly effective strategy to treat a wide range of cancers. However, there are limita..

Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses

Eun Young Kang, Dane Cheasley, Cecile LePage, Matthew J Wakefield, Michelle da Cunha Torres, Simone Rowley, Carolina Salazar, Zhongyue Xing, Prue Allan, David DL Bowtell, Anne-Marie Mes-Masson, Diane M Provencher, Kurosh Rahimi, Linda E Kelemen, Peter A Fasching, Jennifer A Doherty, Marc T Goodman, Ellen L Goode, Suha Deen, Paul DP Pharoah, et al.

Conference Proceedings  |  2021  |  Modern Pathology

TP53 mutations are implicated in the progression of mucinous borderline tumors (MBOT) to mucinous ovarian carcinomas (MOC). Optimi..

Primary mucinous ovarian neoplasms rarely show germ cell histogenesis

Felix KF Kommoss, Dane Cheasley, Matthew J Wakefield, Clare L Scott, Ian G Campbell, C Blake Gilks, Kylie Gorringe

Journal article  |  2020  |  Histopathology

Recently, genetic analyses of primary mucinous ovarian tumours (MOT) have considerably enhanced our understanding of the biology o..

DNA repair gene promoter methylation patterns adapt and influence PARP inhibitor response.

Kasenija Nesic, Rachel M Hurley, Cordelia McGehee, Olga Kondrashova, Maria I Harrell, Giada V Zapparoli, Ashan Musafer, Ming E Wong, John Weroha, Xiaonan Hou, Hu Li, Vivian Negron, Kevin Peterson, Paula Schneider, Elizabeth M Swisher, Melissa Southey, Alexander Dobrovic, Matthew Wakefield, Scott H Kaufmann, Clare L Scott

Conference Proceedings  |  2020  |  CLINICAL CANCER RESEARCH

Abstract PR13: Inhibition of RNA polymerase I transcription activates targeted DNA damage response and enhances the efficacy of PARP inhibitors in high-grade serous ovarian cancer

Elaine Sanij, Katherine Hannan, Jiachen Xuan, Shunfei Yan, Jessica A Ahern, Anna S Trigos, Natalie Brajanovski, Jinbae Son, Keefe T Chan, Olga Kondrashova, Elizabeth Lieschke, Matthew J Wakefield, Sarah Ellis, Carleen Cullinane, Gretchen Poortinga, Kum Kum Khanna, Linda Mileshkin, Grant A McArthur, John Soong, Els M Berns, et al.

Conference Proceedings  |  2020  |  Oral Presentations - Proffered Abstracts

Inhibition of RNA polymerase I transcription activates targeted DNA damage response and enhances the efficacy of PARP inhibitors in high-grade serous ovarian cancer.

Elaine Sanij, Katherine Hannan, Jiachen Xuan, Shunfei Yan, Jessica A Ahern, Anna S Trigos, Natalie Brajanovski, Jinbae Son, Keefe T Chan, Olga Kondrashova, Elizabeth Lieschke, Matthew J Wakefield, Sarah Ellis, Carleen Cullinane, Gretchen Poortinga, Kum Kum Khanna, Linda Mileshkin, Grant A McArthur, John Soong, Els M Berns, et al.

Journal article  |  2020  |  CLINICAL CANCER RESEARCH

Abstract High-grade serous ovarian cancer (HGSOC) accounts for the majority of ovarian cancer and has a dismal prognosis. PARP inh..

Abstract IA02: DNA repair gene promoter methylation patterns adapt and influence PARP inhibitor response

Kasenija Nesic, Rachel M Hurley, Cordelia McGehee, Olga Kondrashova, Maria I Harrell, Giada V Zapparoli, Ashan Musafer, Ming E Wong, John Weroha, Xiaonan Hou, Hu Li, Vivian Negron, Kevin Peterson, Paula Schneider, Elizabeth M Swisher, Melissa Southey, Alexander Dobrovic, Matthew Wakefield, Scott H Kaufmann, Clare L Scott

Conference Proceedings  |  2020  |  Oral Presentations - Invited Abstracts

Inhibition of RNA polymerase I transcription activates targeted DNA damage response and enhances the efficacy of PARP inhibitors in high-grade serous ovarian cancer.

Elaine Sanij, Katherine Hannan, Jiachen Xuan, Shunfei Yan, Jessica A Ahern, Anna S Trigos, Natalie Brajanovski, Jinbae Son, Keefe T Chan, Olga Kondrashova, Elizabeth Lieschke, Matthew J Wakefield, Sarah Ellis, Carleen Cullinane, Gretchen Poortinga, Kum Kum Khanna, Linda Mileshkin, Grant A McArthur, John Soong, Els M Berns, et al.

Conference Proceedings  |  2020  |  Clinical Cancer Research

Oocytes can efficiently repair DNA double-strand breaks to restore genetic integrity and protect offspring health

Jessica M Stringer, Amy Winship, Nadeen Zerafa, Matthew Wakefield, Karla Hutt

Journal article  |  2020  |  Proceedings of the National Academy of Sciences of the United States of America

Female fertility and offspring health are critically dependent on an adequate supply of high-quality oocytes, the majority of whic..

CX-5461 activates the DNA damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancer

Elaine Sanij, Katherine M Hannan, Jiachen Xuan, Shunfei Yan, Jessica E Ahern, Anna S Trigos, Natalie Brajanovski, Jinbae Son, Keefe T Chan, Olga Kondrashova, Elizabeth Lieschke, Matthew J Wakefield, Daniel Frank, Sarah Ellis, Carleen Cullinane, Jian Kang, Gretchen Poortinga, Purba Nag, Andrew J Deans, Kum Kum Khanna, et al.

Journal article  |  2020  |  NATURE COMMUNICATIONS

Acquired resistance to PARP inhibitors (PARPi) is a major challenge for the clinical management of high grade serous ovarian cance..